Biotech/Merck’s sacituzumab tirumotecan is set to supersede chemotherapy in combination with Keytruda in first-line, ...
The Swiss company's candidate has comfortably surpassed Lumakras and Krazati; significant survival data and an impressive ...
Australia’s regulator weighs in on debate about whether intention or function should decide regulatory status for AI products ...
Another positive study for AstraZeneca’s PD-L1 blocker Imfinzi could send it into a third bladder cancer population, while ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results